Accumulating evidences indicate that the cellular and molecular microenvironment of follicular lymphoma (FL) has a key role in both lymphomagenesis and patient outcome. Malignant FL B cells are found admixed to specific stromal and immune cell subsets, in particular CD4 pos T cells displaying phenotypic features of follicular helper T cells (T FH ). The goal of our study was to functionally characterize intratumoral CD4 pos T cells. We showed that CXCR5 hi ICOS hi CD4 pos T cells sorted from FL biopsies comprise at least two separate cell populations with distinct genetic and functional features: (i) CD25 pos follicular regulatory T cells (T FR ), and (ii) CD25 neg T FH displaying a FL-B cell supportive activity without regulatory functions. Furthermore, despite their strong similarities with tonsil-derived T FH , purified FL-derived T FH displayed a specific gene expression profile including an overexpression of several genes potentially involved directly or indirectly in lymphomagenesis, in particular TNF, LTA, IL4 or CD40LG. Interestingly, we further demonstrated that these two last signals efficiently rescued malignant B cells from spontaneous and rituximab-induced apoptosis. Altogether, our study demonstrates that tumor-infiltrating CD4 pos T cells are more heterogeneous than previously presumed, and underlines for the first time the crucial role of T FH in the complex set of cellular interactions within FL microenvironment.
INTRODUCTION
Follicular lymphoma (FL), the most frequent indolent nonHodgkin's lymphoma, results from the transformation of germinal center (GC) B cells. 1 Besides a complex set of intrinsic genetic abnormalities, FL B cells retain, like their normal counterpart, a strong dependence on their molecular and cellular microenvironment. Indeed, malignant B cells are found admixed with specific stromal cell subsets 2 and CD4 pos T cells, 3 which form a specialized malignant cell niche within the invaded lymphoid organs. Importantly, gene expression profile studies performed on whole tissue biopsies have revealed that the outcome of FL patients was not primarily predicted by the gene expression pattern of tumor B cells, but by gene signatures of non-malignant tumor-infiltrating cells, with a favorable outcome related to T-cell-restricted genes. 4 Several reports have confirmed that the nature and the localization of T cells within the invaded lymph nodes (LN) could be used as prognostic biomarkers. Interestingly, the localization of CD4 pos T cells within neoplastic follicles, unlike their absolute number, was consistently associated with poor survival and rapid transformation, 5 suggesting that different CD4 pos T cell subsets could display different functions in FL. Among them, regulatory T cells (Treg) are supposed to have a central role. Surprisingly, an increased number of FOXP3 pos Treg has been first associated with improved overall survival. 6 However, their follicular localization was thereafter associated with poor progression-free and overall survival, as well as a high risk of transformation. 7 Furthermore, convincing functional studies revealed that natural and induced FL Treg were endowed with suppressive capacities towards infiltrating CD4 pos effector T cells and CD8 pos cytotoxic T cells. 8 --10 Overall, these data suggest that, like in solid tumors, Treg inhibit antitumor responses in FL. Other immunohistochemistry studies have focused on markers harbored by follicular helper T cells (T FH ), the specialized subset of CD4 pos T cells present within the secondary lymphoid organs (SLO). T FH provide survival signals to antigen-selected GC B cells, and help them to achieve class-switch recombination and differentiation into antibody-secreting plasma cells. Highly controversial findings were reported, concerning the prognostic value of the number and localization of PD1 pos and CD57 pos T cells. 5,11 --13 However, the phenotypic definition of T FH requires a combination of several markers, thus limiting the impact of single marker-based immunohistochemistry studies. In addition, although we recently identified a T FH -dependent IL-4-centered pathway in FL, no functional study has been performed yet to explore the specific role of the T FH compartment on malignant FL B cells.
T FH are characterized by a strong expression of CXCR5 associated with a lack of CCR7, allowing their migration and retention into the CXCL13-rich light zone of GC. In addition, they express high levels of inducible costimulator (ICOS), CD200, PD-1, and produced IL-21 and CXCL13.
14 These features are essentially associated with the expression of the transcription factor BCL-6, the master regulator of T FH differentiation. 15 Importantly, T FH subset has emerged as an independent CD4 pos T helper lineage with distinct developmental program and effector functions. However, several recent reports revealed a higher plasticity within T helper lineages than previously anticipated. In particular, studies conducted in mice and humans demonstrated that T FH could secrete IFN-g, IL-4 and IL-17, the prototypic Th1, Th2 and Th17 cytokines. 16 --18 Owing to the demonstration that in both mice and human, CXCR5 and ICOS are two of the most relevant phenotypic T FH cell markers, 19, 20 we aimed to fully characterize CXCR5 hi ICOS hi CD4 pos T cells-infiltrating FL tumors. In addition, as human tonsil CD4 pos CD57 pos T FH have been described to exert regulatory functions in vitro, 21 and Treg could localize within malignant follicles in FL 7 , but are essentially found in the extrafollicular zones in reactive LN, 22 
MATERIALS AND METHODS

Cell samples
All tissues used for this study came from subjects recruited under institutional review board approval and informed consent process according to the Declaration of Helsinki. Samples were obtained from the LN of patients with de novo FL, diffuse large B-cell lymphoma (DLBCL), or with reactive non-malignant diseases considered as normal counterpart, and from tonsils collected from children undergoing routine tonsillectomy. All FL LN showed a predominant follicular growth pattern and were classified into grades 1, 2 or 3a, according to the WHO diagnostic criteria. Tissues were cut into pieces and flushed using syringes and needles. The CD4 pos T-cell-enriched fraction was obtained as previously described. 17 hi CD127 low Treg. Th1, Th2 and Th17 clones were obtained from biopsies taken from active inflammatory lesions of patients suffering from chronic inflammatory or auto-immune diseases, as previously described. 24 Quantitative RT-PCR Total RNA was extracted using RNeasy Kit (Qiagen, Valencia, CA, USA). All samples used displayed an RNA integrity number of at least 9.4. cDNA was then generated using Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA, USA). For quantitative RT-PCR, we used assay-on-demand primers and probes (Supplementary Table S1 ), and the Taqman Universal Master Mix from Invitrogen. Gene expression was measured using the ABI Prism 7000, or the ABI Prism 7900HT Sequence Detection System (Life Technologies, Carlsbad, CA, USA), for TaqMan Array Micro Fluidic Cards (Life Technologies). B2M, CASC3, and 18S was determined as appropriate internal standard genes. 25 For each sample, the C T value for the gene of interest was determined, normalized to the geometric mean value of the three housekeeping genes, and compared with the value obtained from a pool of peripheral blood naive CD4 pos T cells. A hierarchical clustering algorithm was used to group genes on the basis of similarity, and data visualization was carried out with Cluster and Treeview (Eisen softwares, Stanford, CA, USA). Supervised analyses included two approaches: (1) Significance Analysis of Microarrays (SAM) software, using 500 permutations, a fold change 42 or o0.5, and a false discovery rate o3%; (2) unpaired Mann --Whitney non-parametric test carried out with Partek Genomics Suite software (Partek, Saint Louis, MO, USA), and selection of gene with a P-value o0.05. Generated gene lists were then crossed to retain only overlapping genes. Principal component analysis was conducted using Partek Genomics Suite.
Flow cytometry characterization
Monoclonal antibodies (mAbs) used are listed on Supplementary Table S2 . Data were analyzed using Kaluza software (Beckman Coulter, Miami, FL, USA). For IL-4 and IFN-g detection, total FL LN or tonsil cell suspensions were stimulated with 100 ng/ml of phorbol 12-myristate 13-acetate and 750 ng/ml of ionomycine for 6 h in RPMI 10% fetal calf serum at 37 1C. In all, 10 mg/ml of brefeldin A (Becton Dickinson) were added for the last 4 h of stimulation. The percentage of viable CD3 pos T cells, non-T FH , and T FHproducing IL-4 and IFN-g was determined by staining with live/dead fixable yellow dead cell stain kit (Invitrogen) and cell-subset gating mAbs before fixation and permeabilization using the Cytofix/Cytoperm Fixation/ Permeabilization Solution Kit (BD Biosciences) and incubation with anti IL-4 or anti-IFN-g mAbs.
Immunohistochemistry studies
Immunohistochemistry was performed on deparaffinized tissue sections of FL LN, reactive LN with follicular hyperplasia and tonsils using a standard indirect avidin-biotin immunoperoxidase method. Briefly, after appropriate antigen retrieval, sections were incubated with anti-human ICOS (provided by Dr T Marafioti) and anti-human FOXP3 (clone 236A/E7 Abcam, Cambridge) mAbs. Double immunostainings were performed as previously described. 26 Images were captured with a Zeiss Axioskop2 microscope (Zeiss, Oberkochen, Germany) and Neofluar Â 100/0.1 NA optical lenses (Zeiss). Photographs were taken with a DP70 Olympus camera (Olympus, Tokyo, Japan). Image acquisition was performed with Olympus DP Controller 2002, and images were processed with Adobe Photoshop v7.0 (Adobe Systems, San Jose, CA, USA).
B-cell anti-apoptotic assay
Purified FL malignant B cells were cultured in IMDM 10% fetal calf serum in round bottom 96-well plates alone or in presence of purified T-cell subsets (ratio 1:1). After 24 h, cells were harvested and B-cell apoptosis was assessed on gated CD20 pos CD4 neg B cells using active caspase-3 PE apoptosis kit (Becton Dickinson), according to manufacturer's instructions. In addition, B-cell activation was evaluated in the same culture conditions after 40 h of culture, by the ratio of the mean fluorescence intensity (RMFI) obtained with phycoerythrin-conjugated CD86mAb and its isotypematched negative control (Beckman Coulter).
Suppression assay
Effector T cells were stained with 5 mM of carboxyfluorescein diacetate succinimidyl ester (CFSE, Invitrogen) and resuspended in IMDM 10% AB human serum, 0.2 mg/ml anti-CD3 (Sanquin, Amsterdam, The Netherlands) and 0.1 mg/ml anti-CD28 (Becton Dickinson) mAbs. Culturing were performed in round bottom 96-well culture plates, in the presence or absence of T FH , non-T FH , Treg or T FR (ratio of 1:1) for 5 days. CFSE pos TOPRO-3 neg viable effector T cells were analyzed. Percentages of cells in each generation were identified using the ModFit software (Verity Software, Topsham, ME, USA).
Rituximab-induced cell death assay
Purified FL malignant B cells were plated in round bottom 96-well plates in IMDM 50% AB human serum, and stimulated or not for 3 h with 50 ng/ml CD40L, 35 ng/ml enhancer polyhistidine mAb and 50 ng/ml IL-4 (RD Systems, Abingdon) before 21 h of culture in the presence or absence of 25 mg/ml anti-CD20mAb rituximab (Mabthera Roche, Basel, Switzerland).
The absolute number of TOPRO-3 neg viable FL B cells was evaluated using Flowcount beads (Beckman Coulter).
Statistical analyses
Statistical analyses were performed with the GraphPad Prism software (GraphPad Software, San Diego, CA, USA) using non-parametric Kruskal --Wallis test, Wilcoxon's test for matched pairs, or Mann --Whitney U tests.
RESULTS
Phenotypic description of CXCR5
hi ICOS hi CD4 pos T cells in reactive and malignant SLO We first quantified by flow cytometry CXCR5
hi ICOS hi CD4 pos T cells in dissociated samples of reactive LN and tonsils, as well as in infiltrated LN from patients with FL and de novo DLBCL. As previously described, 17 we found a similarly high proportion of T FH in tonsils (median: 30% (5 --57)) and FL LN (median: 32% (10 --57)). (Figure 1b ). Because previous data suggested that Treg could be specifically recruited in follicles in FL context, 9 we also decided to characterize this population more precisely. We evaluated the expression of CD25 and FOXP3 among CD4 pos T cells within SLO. We revealed a higher frequency of (Figure 2a) . In order to evaluate whether this phenotype was really associated to a follicular localization, double-immunostainings were performed on FL biopsies and confirmed the presence of numerous FOXP3 pos cells co-expressing ICOS essentially within FL neoplastic follicles (Figure 3a) . On the contrary, these cells were rare in GC of follicular hyperplasia, and were localized in the interfollicular areas or at the periphery of GC (Figure 3b ), in accordance with their homogeneous low expression of CXCR5 in tonsils (Figure 2b ). Finally, although no correlation was found between the proportions of total Treg and T FR in FL samples, we revealed a strong correlation between FL T FR and T FH contents (P ¼ 0.02) (Figure 2c) To further explore the complexity of follicular CD4 pos T cells in FL, we compared the gene expression profiles of ex vivo-sorted Treg, FL-derived T FR , and FL-and tonsil-derived T FH by quantitative RT-PCR. We also included in our analysis Th1, Th2 and Th17 clones derived from chronically inflamed human tissues that were shown to be highly representative of T-cell polarization in humans. 24, 27 This study involved 45 genes that have a pivotal role in CD4 pos T cell differentiation, localization and effector functions (Supplementary Table S1 ). The results of a principal component analysis revealed that FL and tonsil-derived T FH shared a very close gene expression signature, compared with Th1, Th2, Th17, Treg and FL T FR (Figure 4a ). In addition, an unsupervised clustering analysis allowed to properly classify FL-and tonsil-derived T FH , and ordered FL T FR closer to Treg than T FH (Figure 4b ). More precisely, we then focused on the expression of the master regulators of each helper T-cell lineage, that is, TBX21, GATA3, RORC, FOXP3 and BCL6 involved and over-expressed during the Th1, Th2, Th17, Treg and T FH cell differentiation, respectively. We confirmed that FL and tonsil-derived T FH expressed lower to undetectable levels of TBX21, GATA3 and RORC, compared with Th1, Th2 and Th17. In addition, T FR and Treg exhibited a similarly high level of FOXP3, unlike FL and tonsil-derived T FH . FL-and tonsil-derived T FH strongly expressed BCL6 and were devoid of PRDM1 expression, whereas FL T FR strongly expressed PRDM1 (Figure 4c) . Overall, when focusing on T-helper differentiation genes, our data highlighted that FL-derived T FH Figure S1) . These data were helpful to reconcile the discrepancy within FL biopsies, between the percentages of CXCR5 hi CD4 pos T cells co-expressing high levels of ICOS (comprising T FH and T FR ) versus high levels of PD-1 (comprising T FH only) (Figure 1b) , and confirmed that T FR constitute a specific new cell subset distinct from both T FH and Treg. (Figure 5a ). Similarly, T FH , unlike both nonT FH and T FR , were able to rescue autologous malignant B cells from spontaneous apoptosis in vitro (Figure 5b) .
Furthermore, functional studies revealed that although T FR did not display a malignant B-cell supportive effect, they exerted a strong regulatory potential, as demonstrated by their capacity to inhibit CD4 pos CD25 neg effector T-cell proliferation as efficiently as tonsil Treg used as a control (Figures 5b and c) . In the same experiment, paired FL T FH displayed no regulatory properties (Figure 5c ). These results convincingly demonstrated that T FR could be considered as bona fide Treg expressing the GC-specific receptor CXCR5.
In CD40L/CD40 and IL-4/IL-4Ra are involved in FL B cell supportive activity of autologous T FH Despite the similarities between T FH obtained from FL LN and tonsils, we next tried to unravel the specificity of T FH in the malignant context. In fact, the unsupervised clustering analysis described above (Figure 4b ) revealed some discrepancies between these two populations. Statistical analysis using combined SAM and Mann --Whitney U test highlighted a significant differential expression of ten genes, including eight genes upregulated in FL-derived T FH (Table 1) . We focused our attention on three of them: the B-cell-activating cell surface molecule CD40LG, and the prototypic Th1 and Th2 cytokines, IFNG and IL4, previously reported as secreted by murine and human T FH . 17, 28, 29 We confirmed on a more important set of samples the significant over-expression of CD40LG and IL4 in T FH sorted from FL-LN, compared with those isolated from tonsils (Figure 6a ). In addition, we found by flow cytometry that FL LN contained a higher frequency of IFN-g-secreting T cells than tonsils (median: 19.3% (14 --32) and 10.8% (8 --18) for FL LN and tonsils, respectively, Po0.05), in particular in the T FH compartment (median: 8.3% (6 --22) and 4.5% (3 --10), respectively, Po0.05) (Figure 6b) .
Similarly, the frequency of T cell-secreting IL-4 was also more important in FL LN (median: 12.7% (7 --15) ), as compared with tonsils (median: 1.2% (1 --3) , Po0.01), and this cytokine was predominantly produced by the T FH subset (Figure 6c ). Taken together, these results prompted us to evaluate the role of CD40L and IL-4, two molecules implicated in normal B-cell growth, in the supportive effect of FL T FH . Immunohistochemistry in biopsies of (a) two cases of FL (1,2; respectively X100 and X400; 3,4; respectively X100 and X400), and (b) a reactive tonsil (1,2; respectively x100 and X250) and a LN with follicular hyperplasia (3,4; respectively X100 and X250). Double staining for FOXP3 (nuclear, blue) and ICOS (membrane, brown) show only very few cells expressing both markers in reactive tonsils and LN, mainly surrounding reactive GC (arrows) whereas a significant proportion of cells --either scattered or in small clusters -in the neoplastic follicles of FL are double stained for FOXP3 and ICOS.
In order to answer this question, we first cultured FL LN samples in the presence of anti-CD40L and/or anti-IL-4Ra-neutralizing mAbs, and evaluated the survival of malignant FL B cells. We were able to detect a slight but significant inhibition of malignant B-cell survival in the presence of each specific neutralizing antibody. Indeed, anti-CD40L and anti-IL-4Ra mAbs inhibited FL B-cell survival by 11.5% (5.8 --16.3) and 10.4% (1.6 --11.5), respectively (n ¼ 4, data not shown). In order to better underline the direct anti-apoptotic activity of CD40L and IL-4 on FL B cells, we evaluated their impact on the survival of purified FL B cells, in the presence of the specific anti-CD20mAb rituximab, commonly used in the treatment of FL patients. These experiments were performed in the presence of human serum with an undamaged complement activity in order to evaluate the rituximab-mediated complement-dependent cytotoxicity. Malignant B cells displayed a heterogeneous response to rituximab cytotoxicity (median survival: 34% (19 --85)), as previously described. 30 Nevertheless, although CD40L þ IL-4 did not increase spontaneous FL B cell survival during short term culture, we observed a significant but highly variable decrease (median: 45% (3 --100), n ¼ 9) of rituximab-dependent cytotoxicity in the presence of CD40L þ IL-4 ( Figure 6d) . Overall, these results demonstrated that CD40L and IL-4, which are both overexpressed by FL-derived T FH , contributed to FL B-cell survival.
DISCUSSION
FL B cells are characterized by chromosomal aberrations, a strong dependence on BCR signaling, and a bidirectional and dynamic crosstalk with both stromal and hematopoietic microenvironment Abbreviations: AHR, aryl hydrocarbon receptor; IFNG, interferon-gamma; IL, interleukin; LTA, lymphotoxin alpha; RORC, RAR-related orphan receptor C; TNF, tumour necrosis factor. Bold lines correspond to factors validated at the protein level or used for functional assays in Figure 6 .
within follicular malignant niche. Several studies using gene expression profile or immunohistochemistry approaches have depicted the importance of CD4 pos T cells, depending on their number, activation status and localization within malignant follicles. 5, 12 To date, in FL, only few functional studies have been performed essentially focused on Treg. These data prompted us to better characterize the follicular CD4 pos T cells. The primary goal of our study was to precisely define T FH 31 clinical behavior is primarily predicted by tumor cell molecular signatures in aggressive lymphomas, 32 whereas FL patient outcome, including overall survival and risk of transformation, is essentially related to the gene signature of non-malignant infiltrating cells. 4, 33 22 In melanoma, accumulating Treg expressing high levels of ICOS have been reported among tumor-infiltrating T cells. This ICOS hi Treg subset displayed strong suppressive functions, and induced the activation of IL-4-secreting T cells. 34 In addition, we demonstrated the presence of these FL T FR within neoplastic follicles, in accordance with their expression of CXCR5. The specific homing of Treg within neoplastic GC could result from two complementary processes: their specific recruitment or their local induction/expansion. Interestingly, CCL22 secreted by FL B cells has been described as involved in the recruitment of Treg, 9 and previous data reported that malignant B cells contributed to Treg differentiation. 35, 36 Importantly, two recent papers identified in mice, a subset of CXCR5 hi PD1 hi Foxp3 pos suppressive T cells that localize to the GC, coexpress BCL6 and PRDM1, and arise from thymic-derived Foxp3 pos precursors. 37, 38 They called them T FR cells. Our study provides strong evidence that this new T-cell population actually exists in human and is expanded during lymphomagenesis.
Here, we reported a strong correlation between T FR and T FH proportions, suggesting that CXCL13 secreted by T FH could contribute to the recruitment of CXCR5-expressing T FR within neoplastic follicles. In agreement, CXCL13 was similarly highly expressed by tonsil and FL T FH (data not shown). Of note, no correlation between expression of CXCL13 and FOXP3 within FL microenvironment (data not shown), or between the proportion of T FH and total Treg have been found, reinforcing the specific relationship between T FH and T FR . Importantly, a recent report revealed the poor prognosis value of the follicular infiltration of FOXP3 pos cells in FL biopsies. 7 This may suggest that the T FR subset has an important role in FL pathogenesis through the inhibition of anti-tumor immune response. However, the low representation of T FR in the FL microenvironment (median: 3% among CD4 pos T cells) hampered us to perform more detailed functional investigations on this subset.
Beside this T FR subpopulation, we demonstrated the presence of CXCR5 hi ICOS hi CD25 neg CD4 pos T cells sustaining FL B-cell survival and activation, and therefore matching the functional definition of T FH . In addition, this subset brought all the phenotypic features of human tonsil T FH . We were able to show that FL T FH , like tonsil T FH , expressed less TBX21, GATA3, RORC and FOXP3, than Th1, Th2, Th17 clones, and natural Treg, and a higher BCL6/PRDM1 ratio. FL and tonsil T FH also expressed similar levels of IL21 and BTLA. Importantly, no regulatory function was associated to CXCR5 hi ICOS hi FL T FH , contrary to previous data obtained with tonsil CD57 pos T FH . 21 This apparent discrepancy may result from the different phenotypic definitions of T FH . It has been demonstrated that CD57, unlike the CXCR5/ICOS combination, is not an appropriate marker of functional T FH . 20 In addition, we have shown here that it could be more appropriate to define T FH among CD4 pos CD25 neg T cells, as previously hypothesized, 39 in order to reduce the potential contamination by Treg.
A more detailed analysis on selected genes revealed discrepancies between tonsil and FL T FH . In particular, we demonstrated that FL-derived T FH expressed more IFNG, TNF and LTA than tonsilderived T FH . In a previous work, we reported an increased expression of these three genes in the entire microenvironment of FL B cells compared with the normal tissues, and owing to the correlation between IFNG, GRZA, GRZB and CD8A expression, we suggested the implication of cytotoxic cells in this secretion. 23 Here, we demonstrated by quantitative RT-PCR experiments and flow cytometry strategies that T FH were also involved in this overexpression of IFN-g. Of note, this secretion of IFN-g, TNF-a and LT-a by T FH may have an influence on the FL B cell supportive effect of stromal cells, as described previously. 23, 40 In addition, these inflammatory cytokines could also stimulate macrophages, which were shown to have an adverse effect on the outcome of FL patients. 41, 42 We also observed an increased expression of the transcription factor aryl hydrocarbon receptor in FL T FH , compared with tonsil T FH . Aryl hydrocarbon receptor have been reported to regulate Th17, to induce the differentiation of Treg, and to enhance CYP1A1, IL10 or IL22 expression. 43 --45 In the present study, gene expression data did not reveal an increased expression of these three genes in FL T FH . However, it has also been reported that aryl hydrocarbon receptor could physically interact with c-Maf, 43, 46 the transcription factor that specifically promotes IL-4 synthesis in Th2 cells. These two transcription factors could have a key role in the development and the functionality of IL4-producing T FH in FL context.
Finally, FL T FH showed an increased expression of three B-cell growth factors, that is, IL2, IL4 and CD40LG, compared with tonsil T FH . Flow cytometry analyses revealed a higher proportion of IL-4-secreting cells within FL T FH . The CD40/CD40L pathway is central to multiple steps of B-cell survival, activation and differentiation. The growth activity of CD40L has already been demonstrated on neoplastic mature B cells 23 and IL-4 exerts an antiapoptotic activity on normal B cells. 47, 48 Nevertheless, a dual role for IL-4 was demonstrated on DLBCL malignant cells, with an increased sensitivity of GCB-like DLBCL to doxorubicin and rituximab, whereas IL-4 protected ABC-like DLBCL from druginduced apoptosis. 49 In addition, a previous report demonstrated that IL-4 slightly and irregularly enhanced the proliferation of FL B cells in vitro. 50 In our study, we highlighted a strong anti-apoptotic activity of CD40L and IL-4 on FL B cells treated in vitro with rituximab. Interestingly, this anti-apoptotic effect was inversely correlated to the sensitivity of malignant FL B cells to rituximab. Of note, beside its survival potential, IL-4 was also able to drive macrophages toward a TAM phenotype endowed with tumor invasion, immunoregulatory and pro-angiogenic properties. 51 In summary, our results depict new facets of the complex cellular interactions in FL and highlight the important supportive role of T FH in the tumor microenvironment of FL malignant B cells. Targeting T FH and their survival factors in combination with direct antitumor agents might be a promising strategy to provide new therapeutic schemes for FL patients.
